Should I buy or sell Adicet Bio stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adicet Bio in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ACET shares. View ACET analyst ratings or view top-rated stocks .

What is Adicet Bio's stock price target for 2024?

8 brokerages have issued 1 year price targets for Adicet Bio's stock. Their ACET share price targets range from $5.00 to $27.00. On average, they anticipate the company's stock price to reach $12.83 in the next twelve months. This suggests a possible upside of 554.8% from the stock's current price. View analysts price targets for ACET or view top-rated stocks among Wall Street analysts .

How have ACET shares performed in 2024?

Adicet Bio's stock was trading at $1.89 at the beginning of 2024. Since then, ACET stock has increased by 3.7% and is now trading at $1.96. View the best growth stocks for 2024 here .

Are investors shorting Adicet Bio?

Adicet Bio saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 7,690,000 shares, an increase of 32.4% from the March 15th total of 5,810,000 shares. Based on an average trading volume of 1,690,000 shares, the days-to-cover ratio is currently 4.6 days. View Adicet Bio's Short Interest .

When is Adicet Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our ACET earnings forecast .

How were Adicet Bio's earnings last quarter?

Adicet Bio, Inc. (NASDAQ:ACET) announced its earnings results on Tuesday, March, 19th. The company reported ($0.69) EPS for the quarter, beating analysts' consensus estimates of ($0.72) by $0.03.

What ETF holds Adicet Bio's stock?

Loncar China Biopharma ETF holds 140,011 shares of ACET stock, representing 1.45% of its portfolio.

What other stocks do shareholders of Adicet Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adicet Bio investors own include FluoroPharma Medical (FPMI) , Twitter (TWTR) , QUALCOMM (QCOM) , Extreme Networks (EXTR) , General Electric (GE) , Altria Group (MO) , Sirius XM (SIRI) and Adobe (ADBE) .

How do I buy shares of Adicet Bio?

Shares of ACET stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Positive News SentimentPositive News

NASDAQ:ACET

Adicet Bio (ACET) Stock Price, News & Analysis

→ Special FREE offer on stock hotsheets (From DTI) (Ad)

Free ACET Stock Alerts

$1.92

-0.11 (-5.42%)

(As of 11:39 AM ET)

Compare

Today's Range: $1.91
▼
$2.04
50-Day Range: $1.95
▼
$3.27
52-Week Range: $1.10
▼
$7.50

Volume: 212,177 shs
Average Volume: 1.56 million shs
Market Capitalization: $157.77 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $12.83

Get Adicet Bio alerts:

Adicet Bio MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.63 Rating Score
Upside/Downside: 554.8% Upside
$12.83 Price Target
Short Interest: Bearish
9.36% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
$7.50 M Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($1.72) to ($1.84) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.81 out of 5 stars

Medical Sector

395th out of 918 stocks

Pharmaceutical Preparations Industry

176th out of 424 stocks

3.3

Analyst's Opinion

Consensus Rating
Adicet Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on 5 buy ratings, 3 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Adicet Bio has only been the subject of 3 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
9.36% of the outstanding shares of Adicet Bio have been sold short.
Short Interest Ratio / Days to Cover
Adicet Bio has a short interest ratio ("days to cover") of 4.6.
Change versus previous month
Short interest in Adicet Bio has recently increased by 32.36%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Adicet Bio does not currently pay a dividend.
Dividend Growth
Adicet Bio does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ACET.

3.3

News and Social Media Coverage

News Sentiment
Adicet Bio has a news sentiment score of 1.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Adicet Bio this week, compared to 1 article on an average week.
Search Interest
21 people have searched for ACET on MarketBeat in the last 30 days. This is an increase of 91% compared to the previous 30 days.
MarketBeat Follows
Only 6 people have added Adicet Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days.

5.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Adicet Bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $7,500,000.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
29.50% of the stock of Adicet Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
83.89% of the stock of Adicet Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Adicet Bio are expected to decrease in the coming year, from ($1.72) to ($1.84) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Adicet Bio is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Adicet Bio is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Adicet Bio has a P/B Ratio of 0.81. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Darwin

Your Next Portfolio Star: Revealing 2024's Top Stock Pick

We're thrilled to offer you an exclusive look at the #1 Buy & Hold Stock of 2024. This isn't just any report. It's the culmination of rigorous analysis, expert insights, and cutting-edge financial strategies, distilled into a compelling narrative that charts the course of what we believe to be the year's most promising investment. (**By clicking the link you are subscribing to The Wealth Creation Investing Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)

Click here to download your report

About Adicet Bio Stock (NASDAQ:ACET)

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.

ACET Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ACET Stock News Headlines

April 14, 2024 | americanbankingnews.com

Adicet Bio, Inc. (NASDAQ:ACET) Short Interest Update

April 10, 2024 | seekingalpha.com

ACET Adicet Bio, Inc.

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

April 10, 2024 | americanbankingnews.com

Adicet Bio (NASDAQ:ACET) Stock Price Passes Above 200-Day Moving Average of $1.97

April 8, 2024 | businesswire.com

Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference

March 28, 2024 | businesswire.com

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

March 28, 2024 | investorplace.com

The Penny Stock A-List: 7 High-Profile Companies on the Verge of Greatness

March 21, 2024 | finance.yahoo.com

Adicet Bio Inc (ACET) Reports Q4 and Full Year 2023 Financial Results

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

March 21, 2024 | finance.yahoo.com

Are Investors Undervaluing Adicet Bio, Inc. (NASDAQ:ACET) By 41%?

March 21, 2024 | markets.businessinsider.com

Adicet Bio’s Promising Drug Pipeline and Buy Rating Justification

March 20, 2024 | markets.businessinsider.com

Buy Recommendation for Adicet Bio Amid Promising Autoimmune and Cancer Therapy Developments

March 20, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Adicet Bio Amid Promising CAR T-Cell Therapies and Strong Financial Footing

March 20, 2024 | markets.businessinsider.com

JMP Securities Keeps Their Hold Rating on Adicet Bio (ACET)

March 19, 2024 | investorplace.com

ACET Stock Earnings: Adicet Bio Meets EPS for Q4 2023

March 19, 2024 | benzinga.com

Adicet Bio: Q4 Earnings Insights

March 19, 2024 | markets.businessinsider.com

Adicet Bio, Inc Q4 loss drops in line with estimates

March 19, 2024 | businesswire.com

Adicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress

March 11, 2024 | businesswire.com

Adicet Bio to Participate in a Fireside Chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

March 5, 2024 | investorplace.com

3 High-Risk Stocks That Could Pay Off in the Millions

February 29, 2024 | businesswire.com

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

February 27, 2024 | investorplace.com

7 Top-Tier Penny Stocks for a Smart Bet

February 25, 2024 | investorplace.com

7 Biotech Penny Stocks on the Verge of Clinical Trial Victory

February 19, 2024 | finance.yahoo.com

ACET Apr 2024 7.500 call

February 13, 2024 | msn.com

Jones upgrades Adicet to buy, cites upcoming catalysts

February 5, 2024 | finance.yahoo.com

Adicet Bio to Participate in a Fireside Chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

January 25, 2024 | finance.yahoo.com

Adicet Bio, Inc. Announces Closing of $98 Million Public Follow-On Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

See More Headlines

Receive ACET Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adicet Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/19/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: Trading Companies & Distributors
Current Symbol: NASDAQ:ACET
CUSIP: 00444610
CIK: 2034
Web: www.aceto.com
Phone: (650) 503-9095
Fax: N/A
Employees: 143
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $12.83
High Stock Price Target: $27.00
Low Stock Price Target: $5.00
Potential Upside/Downside: +533.7%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.63
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.32)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-142,660,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -56.63%
Return on Assets: -48.16%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 8.41
Quick Ratio: 8.41

Sales & Book Value

Annual Sales: $24.99 million
Price / Sales: 6.66
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.43 per share
Price / Book: 0.83

Miscellaneous

Outstanding Shares: 82,170,000
Free Float: 57,930,000
Market Cap: $166.39 million
Optionable: Optionable
Beta: 1.88

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Mr. Chen Schor BA (Age 52)
CPA, M.B.A., CEO, President & Director
Comp: $899.58k
Dr. Aya Jakobovits Ph.D. (Age 68)
Founder & Independent Director
Comp: $40k
Dr. Blake Aftab Ph.D. (Age 43)
Senior VP & Chief Scientific Officer
Comp: $675.04k
Dr. Francesco Galimi M.D. (Age 56)
Ph.D., Chief Medical Officer & Senior VP
Comp: $680.37k
Mr. Brian Nicholas Harvey (Age 63)
Chief Financial Officer
Comp: $596.79k
Dr. Donald Healey Ph.D. (Age 62)
Chief Technology Officer
Ms. Amy Locke
Chief Human Resource Officer
Dr. Nancy L. Boman M.D.
Ph.D., Senior VP & Chief Regulatory Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ACET Stock Analysis - Frequently Asked Questions

Should I buy or sell Adicet Bio stock right now?: 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adicet Bio in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ACET shares.
View ACET analyst ratings or view top-rated stocks.
What is Adicet Bio's stock price target for 2024?: 8 brokerages have issued 1 year price targets for Adicet Bio's stock. Their ACET share price targets range from $5.00 to $27.00. On average, they anticipate the company's stock price to reach $12.83 in the next twelve months. This suggests a possible upside of 554.8% from the stock's current price.
View analysts price targets for ACET or view top-rated stocks among Wall Street analysts.
How have ACET shares performed in 2024?: Adicet Bio's stock was trading at $1.89 at the beginning of 2024. Since then, ACET stock has increased by 3.7% and is now trading at $1.96.
View the best growth stocks for 2024 here.
Are investors shorting Adicet Bio?: Adicet Bio saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 7,690,000 shares, an increase of 32.4% from the March 15th total of 5,810,000 shares. Based on an average trading volume of 1,690,000 shares, the days-to-cover ratio is currently 4.6 days.
View Adicet Bio's Short Interest.
When is Adicet Bio's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our ACET earnings forecast.

How were Adicet Bio's earnings last quarter?: Adicet Bio, Inc. (NASDAQ:ACET) announced its earnings results on Tuesday, March, 19th. The company reported ($0.69) EPS for the quarter, beating analysts' consensus estimates of ($0.72) by $0.03.
What ETF holds Adicet Bio's stock?: Loncar China Biopharma ETF holds 140,011 shares of ACET stock, representing 1.45% of its portfolio.
What other stocks do shareholders of Adicet Bio own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Adicet Bio investors own include FluoroPharma Medical (FPMI), Twitter (TWTR), QUALCOMM (QCOM), Extreme Networks (EXTR), General Electric (GE), Altria Group (MO), Sirius XM (SIRI) and Adobe (ADBE).
How do I buy shares of Adicet Bio?: Shares of ACET stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ACET) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Adicet Bio (ACET) Stock Price, News & Analysis

Adicet Bio MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Adicet Bio Stock (NASDAQ:ACET)

ACET Stock Price History

ACET Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

ACET Stock Analysis - Frequently Asked Questions

Overall MarketRank^™